Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Qlaris Bio, Inc.
14-day prospective, double-masked, active-controlled, randomized multicenter study comparing QLS-111-FDC and PF latanoprost. Study is comprised of 5 visits.
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
BCVA 1.0 logMAR or better in each eye (equivalent to 20/200)
Diagnosis of mild to moderate OAG or OHT in at least one eye
IOP ≥19 mmHg at 08:00 hour (H) at Qualification Visits following a run-in with PF latanoprost
You may not be if
History of active ocular disease other than mild to moderate OAG/OHT
Prior use of any topical PGA without a clinically meaningful response
Noncompliant with current ocular anti-hypertensive medications or unwilling to be compliant throughout the study
Use of other topical ocular concomitant medications 30 days prior
History of angle closure or a narrow angle, significant ocular trauma, ocular infection, uveitis, intraocular surgery in either eye.
Central corneal thickness in either eye \<470 or \>630 μm
Clinically significant systemic or psychiatric disease, chronic kidney disease, or hypertension, hypotension, or diabetes that is uncontrolled.
Participation in any investigational study within 30 days prior to Screening
Females who are pregnant, nursing, or not using birth control.
